2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors:
- Jonathan P. DuffJDJonathan P. Duff
- Alexis TopjianATAlexis Topjian
- Marc D. BergMBMarc D. Berg
- Melissa ChanMCMelissa Chan
- Sarah E. HaskellSHSarah E. Haskell
- Benny L. JoynerBJBenny L. Joyner
- Javier J. LasaJLJavier J. Lasa
- Sondra J. LeySLSondra J. Ley
- Tia T. RaymondTRTia T. Raymond
- Robert M. SuttonRSRobert M. Sutton
- Mary Fran HazinskiMHMary Fran Hazinski
- Dianne L. AtkinsDADianne L. Atkins
- 4 December 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 138 (23) , E731-E739
Abstract
This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation’s continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the “2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.Keywords
This publication has 25 references indexed in Scilit:
- Part 14: Pediatric Advanced Life SupportCirculation, 2010
- Comparative Study of Nifekalant Versus Amiodarone for Shock-Resistant Ventricular Fibrillation in Out-of-Hospital Cardiopulmonary Arrest PatientsJournal of Cardiovascular Pharmacology, 2010
- Rhythms and outcomes of adult in-hospital cardiac arrest*Critical Care Medicine, 2010
- Multicenter cohort study of in-hospital pediatric cardiac arrest*Pediatric Critical Care Medicine, 2009
- In-hospital versus out-of-hospital pediatric cardiac arrest: A multicenter cohort study*Critical Care Medicine, 2009
- Epidemiology and Outcomes From Out-of-Hospital Cardiac Arrest in ChildrenCirculation, 2009
- Outcomes of In-Hospital Ventricular Fibrillation in ChildrenNew England Journal of Medicine, 2006
- Part 12: Pediatric Advanced Life SupportCirculation, 2005
- Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular FibrillationNew England Journal of Medicine, 2002
- Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular FibrillationNew England Journal of Medicine, 1999